Open AccessCOMBINATION THERAPY FOR MYELOFIBROSIS
Author(s) -
И. В. Грибкова,
Ю. А. Олейник,
Sergey Shalaev,
М. В. Давыдовская,
K. Kokushkin
Publication year - 2019
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2019-64-2-188-197
Subject(s) - ruxolitinib , myelofibrosis , medicine , panobinostat , clinical trial , combination therapy , disease , oncology , intensive care medicine , bone marrow , biochemistry , chemistry , histone deacetylase , gene , histone
. Ruxolitinib presents itself as a drug for the pathogenetic treatment of myelofibrosis (MF). New drugs have recently been developed for the treatment of MF. A search for optimal combinations of these drugs with ruxolitinib appears to be a logical approach to the development of MF therapy. Aim. To summarize data on the use of ruxolitinib in combination with various drugs approved or currently being studied in terms of their applicability for MF treatment. General findings. The review analyses data in publications retrieved from the PubMed and Elibrary.ru databases, including clinical cases, original research papers and reviews. We discuss preliminary results of clinical trials of various rational combination therapies, which have demonstrated a high efficacy for the forms of the disease untreatable with ruxolithinib monotherapy, e.g. bone marrow fibrosis and anemia. Combinations of ruxolithinib with azacytidine, panobinostat and α-interferon have shown the most promising results.